The five-day 2026 Annual Meeting of the Association for Diagnostic and Laboratory Medicine (ADLM 2026, formerly the AACC Annual Meeting) successfully concluded on July 30 in Anaheim, California. As the world’s premier and largest industry event in the field of in vitro diagnostics, this year’s exhibition brought together laboratory professionals from over 100 countries, leading scientific experts, and global IVD companies to exchange ideas. DanDa Bio showcased its full range of innovative diagnostic products at Booth 1204, successfully hosting a series of technical discussions and industry collaboration initiatives targeting the global market, and returned with significant achievements.

At this overseas trade show, DIAGREAT Bio fully showcased its integrated industrial capabilities—spanning in-house R&D of raw materials, reagents, complete equipment, quality control, and supporting consumables. Several of its core products attracted domestic and international buyers to stop and inquire, as well as try them out on-site, making the booth a major draw.

As the core product highlighting its competitive edge at this exhibition, DIAGREAT showcased a comprehensive, fully automated TDM monitoring solution for both chemical drugs and biologics. The complete system consists of three interconnected modules: a fully automated drug concentration sample pretreatment system, a chemiluminescence TDM analyzer, and drug concentration prediction software based on pharmacokinetic models. This integrated, one-stop hardware-and-software solution directly addresses the global challenges in clinical precision drug monitoring.

A fully automated chemiluminescence platform with over 70 test items, covering routine immunological assays such as inflammation, myocardial function, gastric function, and cytokines; a portable POCT rapid testing solution with over 70 test items, suitable for rapid screening in emergency departments, primary care settings, and at the bedside; and over 60 rapid test kits for drug-resistant bacteria, meeting multi-level clinical testing needs.

We independently mass-produce key upstream raw materials—such as antigens, antibodies, labeled microspheres, and magnetic beads—which offer high stability and minimal batch-to-batch variation. We provide one-stop customized raw material development services for global diagnostic companies, breaking down barriers in the overseas raw material supply chain and showcasing China’s breakthroughs in the R&D of upstream biological raw materials.

With a fully integrated and controllable end-to-end industry chain, DIAGREAT Bio is able to provide one-stop, customized solutions—ranging from core raw materials and supporting reagents to automated testing equipment—tailored to the diverse needs of laboratories in different countries and at various levels, establishing itself as a highly recognizable force of Chinese innovation at the exhibition

For more than 70 years, ADLM has consistently served as a core platform for identifying global trends in clinical laboratory medicine and connecting global industry resources. DanDa Bio’s continuous participation on the ADLM international stage for many years is a key reflection of the steady progress of its globalization strategy. Over the years, DIAGREAT Bio has remained committed to independent R&D, establishing a closed-loop industrial chain that spans core upstream raw materials, midstream diagnostic reagents, and downstream automated testing equipment. The company continues to strengthen its focus on key growth areas such as TDM (Therapeutic Drug Monitoring), fully automated chemiluminescence, and POCT (Point-of-Care Testing), while continuously refining standardized and localized product solutions tailored to the global market. This trip to Anaheim not only enabled DIAGREAT Bio to fully engage with cutting-edge international technological concepts and accurately gauge global laboratory market demands but also built broader bridges for global collaboration. Moving forward, DIAGREAT Bio will continue to expand its overseas market presence. Leveraging its self-developed, full-chain technological advantages, the company will deliver cost-effective and highly stable domestic diagnostic solutions to help global medical institutions achieve more efficient and precise clinical testing, thereby contributing Chinese corporate strength to the development of precision medicine worldwide.

The event has come to a close, but our journey continues. With ADLM 2026 successfully concluded, DIAGREAT Bio embarks on a new chapter, enriched with recognition and opportunities. We look forward to continuing to collaborate with colleagues in the global diagnostics community to safeguard human health through innovative diagnostic technologies and jointly explore a new future for the in vitro diagnostics industry!